Survodutide

Compound Overview

Survodutide (BI 456906) is a dual-acting peptide studied for activity at both GLP-1 and glucagon receptors. In controlled research settings, the glucagon-receptor component is examined alongside GLP-1-mediated metabolic signaling in models involving hepatic lipid metabolism, energy-expenditure pathways, and liver-targeted metabolic biology.

Research Background & Published Literature

The Survodutide program was developed by Boehringer Ingelheim/Zealand Pharma. Published Phase 2 data in Lancet and trial registries for the SYNCHRONIZE program discuss metabolic parameters and liver-related endpoints, including MASH (metabolic dysfunction-associated steatohepatitis), as clinical-study endpoints.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Sanyal et al. (2024) — N Engl J Med
• Kaplan et al. (2026) — Nat Med

Storage, Handling & Stability Guidelines

Store lyophilized Survodutide at -20°C for long-term stability. After reconstitution with sterile diluent, keep material refrigerated at 2–8°C and limit freeze-thaw exposure by aliquoting working volumes according to your laboratory's standard operating procedures.

• Keep time at ambient temperature as short as practical during handling to support compound integrity.
• Reseal vials promptly after each withdrawal to limit moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.

Lab Verification

Nexus maintains batch-level verification records for research compounds in the Lab Verified archive, including HPLC purity review and Mass Spectrometry identity confirmation where current lot data is available.